Fenebrutinib is currently the only reversible, non-covalent inhibitor of BTK in late-stage development, which Roche maintains could translate into a cleaner side effect profile than other drugs in ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...